Josh Jennings
Stock Analyst at Morgan Stanley
(2.55)
# 2,227
Out of 5,141 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $17.15 | +209.04% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $241.89 | +24.02% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $2.98 | +571.14% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $17.87 | +252.55% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.64 | +993.75% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $79.78 | -49.86% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $17.15
Upside: +209.04%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $241.89
Upside: +24.02%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $2.98
Upside: +571.14%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $17.87
Upside: +252.55%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.64
Upside: +993.75%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $79.78
Upside: -49.86%